{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    7,
    8,
    9,
    10,
    11,
    19,
    20,
    21,
    23,
    24,
    25,
    26,
    27
  ],
  "modelUsed": "gemini-3-pro-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "ALXN1840",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Participants receive ALXN1840 15 mg/day for approximately 28 days followed by titration up to 30 mg/day starting on Day 29."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Cohort 1 (Treatment-experienced)",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who have received Wilson Disease therapy for > 28 days"
      },
      {
        "id": "cohort_2",
        "name": "Cohort 2 (Treatment-naïve)",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who have received Wilson Disease therapy for ≤ 28 days"
      }
    ],
    "summary": {
      "armCount": 1,
      "cellCount": 3,
      "cohortCount": 2
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        },
        {
          "code": "Basic Science",
          "codeSystem": "USDM",
          "decode": "Basic Science"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Non-Randomized",
        "codeSystem": "USDM",
        "decode": "Non-Randomized"
      },
      "armIds": [
        "arm_1"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Hepatology",
        "Rare Diseases"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment",
        "Basic Science"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Non-Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": null,
      "therapeuticAreas": [
        "Hepatology",
        "Rare Diseases"
      ]
    },
    "arms": [
      {
        "name": "ALXN1840",
        "type": "Experimental Arm",
        "description": "Participants receive ALXN1840 15 mg/day for approximately 28 days followed by titration up to 30 mg/day starting on Day 29."
      }
    ],
    "cohorts": [
      {
        "name": "Cohort 1 (Treatment-experienced)",
        "characteristic": "Patients who have received Wilson Disease therapy for > 28 days"
      },
      {
        "name": "Cohort 2 (Treatment-naïve)",
        "characteristic": "Patients who have received Wilson Disease therapy for ≤ 28 days"
      }
    ],
    "epochs": [
      {
        "name": "Run-in Period",
        "description": "Day -7 through Day -1. Includes diet equilibration and measurement of pretreatment copper and molybdenum balance."
      },
      {
        "name": "Treatment Period 1 (15 mg)",
        "description": "Day 1 through approximately Day 28. Participants receive ALXN1840 15 mg/day. Includes Inpatient Period 1 (Day 1-9) and an Outpatient Period."
      },
      {
        "name": "Treatment Period 2 (30 mg)",
        "description": "Day 29 through Day 40. Participants titrate to ALXN1840 30 mg/day. Includes Inpatient Period 2."
      }
    ]
  }
}